#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	2860	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2804	244.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1834	1834	C	329	C,A,G,T	302,3,2,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	2860	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2804	244.5	0	HET	.	.	.	C207T	.	207	207	C	857	857	C	307	C,T	228,52	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	5122	23S	2890	2890	99.9	23S.l6.c4.ctg.1	4046	312.8	0	.	n	.	0	T695C	SNP	695	695	T	1271	1271	C	402	C,A,T	380,3,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	5122	23S	2890	2890	99.9	23S.l6.c4.ctg.1	4046	312.8	0	.	n	.	0	A1638G	SNP	1638	1638	A	2214	2214	G	327	G,A,T	166,151,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	5122	23S	2890	2890	99.9	23S.l6.c4.ctg.1	4046	312.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2547	2547	C	346	C,G,T	329,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	5122	23S	2890	2890	99.9	23S.l6.c4.ctg.1	4046	312.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2621	2621	A	340	A,G	322,3	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	5122	23S	2890	2890	99.9	23S.l6.c4.ctg.1	4046	312.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	3173	3173	C	409	C,G,T	390,2,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	372	folP	855	855	100.0	folP.l15.c4.ctg.1	1960	46.7	1	SNP	p	R229S	1	.	.	685	687	AGC	1269	1271	AGC	46;47;47	A;G;C	45;46;45	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	880	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3867	55.8	1	SNP	p	S91F	1	.	.	271	273	TTC	817	819	TTC	49;49;49	T;T,A;C	43;45,1;46	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	880	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3867	55.8	1	SNP	p	G95N	0	.	.	283	285	GGC	829	831	GGC	53;53;53	G;G,T;C,A	50;49,1;49,1	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	880	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3867	55.8	1	SNP	p	D95G	1	.	.	283	285	GGC	829	831	GGC	53;53;53	G;G,T;C,A	50;49,1;49,1	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	402	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1837	53.8	1	SNP	p	G45D	0	.	.	133	135	GGC	754	756	GGC	89;90;90	G;G;C	82;82;83	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	210	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c4.ctg.1	1585	32.5	0	.	n	.	0	A197.	DEL	197	197	A	879	879	A	71	A	70	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	850	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3528	59.8	1	SNP	p	D86N	0	.	.	256	258	GAC	920	922	GAC	63;62;67	G;A;C	53;42;53	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	850	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3528	59.8	1	SNP	p	R87I	0	.	.	259	261	CGT	923	925	CGT	68;68;69	C;G;T	56;49;50	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	850	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3528	59.8	1	SNP	p	S87R	1	.	.	259	261	CGT	923	925	CGT	68;68;69	C;G;T	56;49;50	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	850	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3528	59.8	1	SNP	p	R87W	0	.	.	259	261	CGT	923	925	CGT	68;68;69	C;G;T	56;49;50	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	850	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3528	59.8	1	SNP	p	S88P	0	.	.	262	264	TCC	926	928	TCC	69;69;69	T;C,A,T;C	63;55,2,1;63	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	726	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3219	55.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1824	1826	GGC	56;57;58	G;G;C	52;54;52	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	826	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2455	80.5	1	SNP	p	A311V	0	.	.	931	933	GCC	1298	1300	GCC	110;111;111	G,A,C;C,A;C,T,A	99,2,1;106,1;105,1,1	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	826	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2455	80.5	1	SNP	p	I312M	1	.	.	934	936	ATG	1301	1303	ATG	111;111;110	A,G;T,A,G;G	103,1;105,1,1;103	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	826	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2455	80.5	1	SNP	p	T316P	0	.	.	946	948	ACC	1313	1315	ACC	111;111;110	A,G;C;C,T	102,2;106;104,1	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	826	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2455	80.5	1	SNP	p	V316T	1	.	.	946	948	ACC	1313	1315	ACC	111;111;110	A,G;C;C,T	102,2;106;104,1	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	826	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2455	80.5	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1814	1816	ACC	102;101;101	A;C,G,A;C,A	88;83,1,1;93,1	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	826	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2455	80.5	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1868	1870	GCG	92;92;92	G;C;G,T	81;78;81,2	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	826	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2455	80.5	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1868	1870	GCG	92;92;92	G;C;G,T	81;78;81,2	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	826	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2455	80.5	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1991	1993	GGT	78;78;78	G,T;G,T;T	73,1;72,1;73	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	826	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2455	80.5	1	SNP	p	G545S	1	.	.	1633	1635	AGC	2000	2002	AGC	76;76;75	A;G;C,T	63;71;59,1	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	826	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2455	80.5	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2018	2020	CCG	68;65;65	C;C,G;G,C	55;52,1;54,1	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1214	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	3561	83.7	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1832	1834	CCG	111;111;111	C;C,A;G,C	93;103,1;91,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	428	porA	1146	1146	99.91	porA.l15.c4.ctg.1	2367	44.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	792	792	C	45	C,G	43,1	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	476	porB1b	1038	1038	100.0	porB1b.l15.c4.ctg.1	2197	53.8	1	SNP	p	G120K	1	.	.	358	360	AAG	925	927	AAG	72;72;72	A,T,C;A;G,A	67,1,1;69;65,3	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	476	porB1b	1038	1038	100.0	porB1b.l15.c4.ctg.1	2197	53.8	1	SNP	p	A121N	1	.	.	361	363	AAC	928	930	AAC	72;72;72	A,C;A;C,A	64,4;70;68,1	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	476	porB1b	1038	1038	100.0	porB1b.l15.c4.ctg.1	2197	53.8	1	SNP	p	N121D	0	.	.	361	363	AAC	928	930	AAC	72;72;72	A,C;A;C,A	64,4;70;68,1	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1748	rpoB	4179	4179	99.98	rpoB.l6.c4.ctg.1	5421	79.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	262	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1670	38.9	1	SNP	p	V57M	1	.	.	169	171	ATG	813	815	ATG	80;81;81	A;T;G	79;80;80	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
